Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour
In forensic settings, the most common indication for clozapine is treatment-resistant schizophrenia (TRS). Clozapine has also been shown to be effective in reducing hostility, aggression and violence in patients with schizophrenia and is of benefit in comorbid substance use disorders. The decision t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2021-01-01
|
| Series: | BJPsych Open |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2056472420001349/type/journal_article |
| _version_ | 1811156911950659584 |
|---|---|
| author | Hein Bokern Niels Jonker Dan Cohen |
| author_facet | Hein Bokern Niels Jonker Dan Cohen |
| author_sort | Hein Bokern |
| collection | DOAJ |
| description | In forensic settings, the most common indication for clozapine is treatment-resistant schizophrenia (TRS). Clozapine has also been shown to be effective in reducing hostility, aggression and violence in patients with schizophrenia and is of benefit in comorbid substance use disorders. The decision to initiate or to discontinue recently initiated clozapine can have a profound beneficial or detrimental influence on the lives and safety of patients and the staff caring for them. We present a case in which treatment with clozapine proved effective in spite of earlier repeated discontinuation of clozapine out of fear of neuroleptic malignant syndrome (NMS). Elevation of creatine kinase was deemed to be indicative of NMS in the absence of clinical signs of NMS. In somatic medicine, it is well known that creatine kinase elevation has many causes, most of them non-harmful. Collaboration with clinical chemistry was shown to be very useful, if not essential; research in the 1980s found replicated evidence for both sex and race differences in creatine kinase levels. In addition, substantial intra-individual variation has been found over time in healthy individuals. The creatine kinase levels of this patient of African descent were within normal limits for the African population. Baseline creatine kinase assessment and repetition of this assessment after 2 weeks with careful interpretation are recommended in all clozapine-treated patients. The authors advocate the introduction of evidence-based creatine kinase cut-off points that reflect the biological differences between the sexes and among races. More intensive contact between psychiatrists and clinical chemist can facilitate faster diagnosis and better treatment. |
| first_indexed | 2024-04-10T04:59:04Z |
| format | Article |
| id | doaj.art-5980248cfeb047069ea4fb5e1e4b6750 |
| institution | Directory Open Access Journal |
| issn | 2056-4724 |
| language | English |
| last_indexed | 2024-04-10T04:59:04Z |
| publishDate | 2021-01-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | BJPsych Open |
| spelling | doaj.art-5980248cfeb047069ea4fb5e1e4b67502023-03-09T12:29:06ZengCambridge University PressBJPsych Open2056-47242021-01-01710.1192/bjo.2020.134Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviourHein Bokern0https://orcid.org/0000-0002-0244-7573Niels Jonker1Dan Cohen2Dr. S. van Mesdag Forensic Psychiatric Center, Groningen, The NetherlandsCerte, Wilhelmina Hospital, Assen, The NetherlandsCommunity Psychiatry Heerhugowaard, Mental Health Organization North-Holland North, The NetherlandsIn forensic settings, the most common indication for clozapine is treatment-resistant schizophrenia (TRS). Clozapine has also been shown to be effective in reducing hostility, aggression and violence in patients with schizophrenia and is of benefit in comorbid substance use disorders. The decision to initiate or to discontinue recently initiated clozapine can have a profound beneficial or detrimental influence on the lives and safety of patients and the staff caring for them. We present a case in which treatment with clozapine proved effective in spite of earlier repeated discontinuation of clozapine out of fear of neuroleptic malignant syndrome (NMS). Elevation of creatine kinase was deemed to be indicative of NMS in the absence of clinical signs of NMS. In somatic medicine, it is well known that creatine kinase elevation has many causes, most of them non-harmful. Collaboration with clinical chemistry was shown to be very useful, if not essential; research in the 1980s found replicated evidence for both sex and race differences in creatine kinase levels. In addition, substantial intra-individual variation has been found over time in healthy individuals. The creatine kinase levels of this patient of African descent were within normal limits for the African population. Baseline creatine kinase assessment and repetition of this assessment after 2 weeks with careful interpretation are recommended in all clozapine-treated patients. The authors advocate the introduction of evidence-based creatine kinase cut-off points that reflect the biological differences between the sexes and among races. More intensive contact between psychiatrists and clinical chemist can facilitate faster diagnosis and better treatment.https://www.cambridge.org/core/product/identifier/S2056472420001349/type/journal_articleSchizophreniaclozapineside-effectscreatine kinaseneuroleptic malignant syndrome |
| spellingShingle | Hein Bokern Niels Jonker Dan Cohen Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour BJPsych Open Schizophrenia clozapine side-effects creatine kinase neuroleptic malignant syndrome |
| title | Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour |
| title_full | Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour |
| title_fullStr | Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour |
| title_full_unstemmed | Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour |
| title_short | Creatine kinase elevation and discontinuation of clozapine: fear-driven clinical practice in a forensic case with treatment-resistant schizophrenia and persistent violent behaviour |
| title_sort | creatine kinase elevation and discontinuation of clozapine fear driven clinical practice in a forensic case with treatment resistant schizophrenia and persistent violent behaviour |
| topic | Schizophrenia clozapine side-effects creatine kinase neuroleptic malignant syndrome |
| url | https://www.cambridge.org/core/product/identifier/S2056472420001349/type/journal_article |
| work_keys_str_mv | AT heinbokern creatinekinaseelevationanddiscontinuationofclozapinefeardrivenclinicalpracticeinaforensiccasewithtreatmentresistantschizophreniaandpersistentviolentbehaviour AT nielsjonker creatinekinaseelevationanddiscontinuationofclozapinefeardrivenclinicalpracticeinaforensiccasewithtreatmentresistantschizophreniaandpersistentviolentbehaviour AT dancohen creatinekinaseelevationanddiscontinuationofclozapinefeardrivenclinicalpracticeinaforensiccasewithtreatmentresistantschizophreniaandpersistentviolentbehaviour |